Majority of Physicians Fear Another Prescription Drug Crisis, Finds New Quest Diagnostics Health Trends™ Report
First-of-its-kind study shows nearly three in four physicians trust their patients to take controlled substances as prescribed, yet half of all patient test results show misuse of these drugs
Non-prescribed gabapentin use accelerating, growing 40% in past year, making it the most commonly detected non-prescribed controlled medication in tested patients

SECAUCUS, N.J., Oct. 16, 2019 /PRNewswire/ -- Most primary care physicians (62%) fear the opioid drug crisis will be traded for a new prescription drug crisis and nearly three quarters (72%) worry that chronic pain patients will turn to illicit drugs if they do not have access to prescription opioids, according to a new Health Trends™ report from Quest Diagnostics (NYSE: DGX). Seventy percent of primary care physicians wish they had more training on how to taper their patients off opioids.

The new report, "Drug Misuse in America 2019: Physician Perspectives and Diagnostics Insights on the Evolving Drug Crisis," provides novel insights into physicians' concerns about patient misuse of prescription and other drugs, as compared with results of objective lab data: half of test results of patients prescribed an opioid or other controlled medication (51%) show signs of drug misuse and one in four (24%) show signs of potentially dangerous drug mixing.

The first-of-its kind report includes findings from a new online survey of 500 U.S. primary care physicians, conducted by The Harris Poll, and commissioned by Quest Diagnostics in consultation with Center on Addiction, about the use of controlled prescribed medications, such as opioids, amphetamines, and benzodiazepines, and illicit drugs. It juxtaposes the survey responses with an analysis of more than 4.4 million de-identified aggregated drug monitoring test results ordered by physicians for patients prescribed controlled medications and performed by Quest Diagnostics between 2011 and 2018.

The intersection of these two data sets reveals, for the first time, the contrast between physician expectations about patient drug use and the evolution of the drug epidemic and actual patient behavior, as revealed by objective lab data, amid a national drug crisis that claimed an estimated 68,500 lives last year.i

The full report is available at

"Quest Diagnostics undertook this research so that we could provide insights into the evolving drug crisis and the potential role of physicians' perspectives about their patients in drug misuse and use disorders," said report co-author Harvey W. Kaufman, M.D., Senior Medical Director and Director, Health Trends Research Program, Quest Diagnostics. "We found that primary care physicians, who are on the front lines of the drug epidemic, are well-intentioned but under-prepared and may miss some of the drug misuse risks affecting their patients, as reflected by our nationally representative laboratory data."

Among the key findings:

Physicians may be overconfident in their ability to recognize prescription drug misuse:

  • One in two patient test results (51%) showed misuse of a controlled medication or other drugs in 2018, a rate that is virtually unchanged from a misuse rate of 52% in 2017 and 2016. Yet, 72% of physicians trust their patients to take their controlled substances as prescribed.
  • Nearly all physicians (95%) feel confident in their ability to discuss risks of prescription drug misuse with patients, but only 55% said they actually discussed potential misuse with most of their patients who were prescribed controlled substances in the past month.

Drug mixing, the most prevalent form of drug misuse, is underestimated by physicians:

  • Most physicians (53%) believe that less than 20% of patients misuse their controlled substances through drug mixing. However, 24% of all patient test results in 2018 showed signs of combining prescription medications with other non-prescribed drugs or substances, including illicit drugs.
  • Drug combining involving fentanyl is also prevalent. Among patient test results that were positive for heroin, 64% were positive for non-prescribed fentanyl. Among patient test results that were positive for cocaine, 24% were positive for non-prescribed fentanyl. The company's testing detects prescription forms of fentanyl, not illicitly manufactured fentanyl, so it is possible actual rates of fentanyl drug combining are even higher.

Gabapentin is emerging as an alternative pain therapy to opioids — just as misuse increases:

  • 78% of physicians say that in an effort to avoid prescribing opioids for the treatment of chronic pain, they often prescribe gabapentin to their patients.
  • Laboratory data show a 40% increase in non-prescribed gabapentin misuse in just the past year, with 13.4% of patient results showing this type of misuse -- making gabapentin the most commonly detected non-prescribed controlled medication in 2018.

Gabapentin, an anticonvulsant that can be used to relieve neuropathic pain, has recently been classified as a controlled substance in some states.

"A vast majority of physicians recognize the need for more tools to prevent opioid drug misuse and substance use disorders, and that is why many are tightening opioid prescribing and turning to gabapentin as an alternative," said report co-author and practicing pain specialist Jeffrey Gudin, M.D., Senior Medical Advisor, Prescription Drug Monitoring, Quest Diagnostics. "While gabapentin may not have opioids' addictive potential, it can exaggerate euphoric effects when combined with opioids or anxiety medications. This drug mixing is dangerous."

Physicians call for more education to combat crisis, cite role of stigma in patient care

Many physicians have called for additional training and education regarding substance use disorders. At least 7 out of 10 physicians would like more information on how to monitor for prescription drug addiction (76%), wish they had more training on what to do if a patient shows signs of addiction (75%) or wish they had more training on how to taper their patients off opioids (70%). A full 88% say prescription drug monitoring (involving laboratory testing) is critical to helping identify patients who may be misusing prescription drugs and 92% believe prescription drug monitoring will increasingly become the standard of care when prescribing controlled substances, although some worry about offending patients (33%).

In addition, 77% of physicians say they believe the stigma surrounding prescription drug addiction impairs patient care.

"The results of this national survey, combined with Quest's data, confirm the need to ensure physicians are equipped to recognize and treat addiction among their patients. Given the frequency of misuse, this issue is clearly more widespread than people think," said Creighton Drury, Chief Executive Officer, Center on Addiction.

The Health Trends report involves an analysis of nationally representative de-identified laboratory data based on testing performed by Quest Diagnostics. It also involves an online survey conducted by The Harris Poll on behalf of Quest Diagnostics and Center on Addiction between July 31–August 16, 2019 among 500 physicians who specialize in family practice, general practice, or internal medicine and are licensed in the state where they practice. Results were weighted for years in practice by gender and region to align them with their actual proportions in the population. The report's methodology, including strengths and limitations, is described in the report, which is available for download at

About Quest Diagnostics Health Trends™
Quest Diagnostics Health Trends™ is a series of scientific reports that provide insights into health topics, based on analysis of objective clinical laboratory data, to empower better patient care, population health management and public health policy. The reports are based on the Quest Diagnostics database of 48 billion de-identified laboratory test results, believed to be the largest of its kind in healthcare. Health Trends has yielded novel insights to aid the management of allergies and asthma, prescription drug monitoring, diabetes, Lyme disease, heart disease, influenza and workplace wellness. Quest Diagnostics also produces the Drug Testing Index (DTI)™, a series of reports on national workplace drug positivity trends based on the company's employer workplace drug testing data.

About Center on Addiction
Center on Addiction merged with Partnership for Drug-Free Kids in January 2019 and is the nation's leading science-based nonprofit dedicated to transforming how the nation addresses addiction. We empower families to support loved ones, advance effective addiction care and shape public policies that prevent and treat addiction as a public health issue. Center on Addiction is the only national organization committed to supporting the whole family as it addresses every aspect of substance use and addiction, from prevention to recovery. For more information, visit

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 46,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

i Ahmad FB, Escobedo LA, Rossen LM, Spencer MR, Warner M, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2019.

Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

SOURCE Quest Diagnostics

For further information: Media, Kim Gorode, 973-520-2800; Ellen Murphy (Syneos), 917-628-8097; Investors, Shawn Bevec, 973-520-2900